The current price of SRPT is $17.57 — it has decreased by 7.48% since the previous close. Data as of Nov 5, 2026.
SRPT is down 7.72% over the past week, up 0.46% over the past month and down 5.89% over the past year. The price is below its 200-day moving average of $18.69.
Analysts' average 12-month price target for SRPT is $21.60, which implies 22.94% upside from the current price. Individual estimates range from $17.00 to $27.00.
Of the 24 analysts covering Sarepta Therapeutics, Inc., 7 rate it a buy, 12 rate it a hold, 3 rate it a sell and 2 rate it a strong sell. The overall consensus is neutral. Analyst ratings are opinions and do not guarantee future performance.
Sarepta Therapeutics, Inc. has a market capitalization of $1.86B. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.
In its most recent quarterly report, Sarepta Therapeutics, Inc. posted a loss of $0.05 per share against an estimate of $0.2173, missing expectations by 123.01%. Upcoming reports are listed in the earnings calendar.
Sarepta Therapeutics, Inc. reported revenue of $401.25M in its most recent quarter, which has decreased by 34.34% compared with the same quarter a year earlier. Analysts had expected $366.39M.
Sarepta Therapeutics, Inc. has not paid any dividends over the past year.
Companies most comparable to Sarepta Therapeutics, Inc. include Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., PTC Therapeutics, Inc., Dyne Therapeutics, Inc. and Intellia Therapeutics, Inc.
In the latest trading session SRPT moved between $17.46 and $18.92, a range of 8.31% of its current price.
Investing in stocks requires thorough research: study the company's financials, related news and technical analysis before making a decision. Technical analysis of Sarepta Therapeutics, Inc. shows a strong sell rating today and a sell rating on the weekly timeframe. Technical ratings are indicators, not investment advice.
Over the past 52 weeks SRPT has traded between $14.68 and $24.68. The current price is 28.81% below its 52-week high.
Figures as of Nov 5, 2026. This information is provided for general purposes only and is not investment advice.